(pak-RIH-tih-nib SIH-trayt)
This page contains brief information about pacritinib citrate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Pacritinib citrate is approved to treat adults with:
- Myelofibrosis (a bone marrow disease) that is intermediate or high risk with a very low platelet count, including the following types:
- Primary myelofibrosis.
- Post-polycythemia vera myelofibrosis.
- Post-essential thrombocythemia myelofibrosis.
Pacritinib citrate is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit in these patients.
Pacritinib citrate is also being studied in the treatment of other conditions.
More About Pacritinib Citrate
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Pacritinib Citrate – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Pacritinib Citrate – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
